These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35584865)

  • 21. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
    Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
    Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
    Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical experience of using brentuximab-vedotin as therapy in relapsed/refractory Hodgkin's lymphoma at Hospital Guillermo Grant Benavente, Concepción, Chile].
    Vidal C; Figueroa F; Briones V; Micolich V; Chandia M
    Rev Med Chil; 2023 Oct; 151(10):1361-1366. PubMed ID: 39093139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
    Younes A; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Ramchandren R; Bartlett NL; Cheson BD; de Vos S; Forero-Torres A; Moskowitz CH; Connors JM; Engert A; Larsen EK; Kennedy DA; Sievers EL; Chen R
    J Clin Oncol; 2012 Jun; 30(18):2183-9. PubMed ID: 22454421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
    Koga Y; Sekimizu M; Iguchi A; Kada A; Saito AM; Asada R; Mori T; Horibe K
    Int J Hematol; 2020 May; 111(5):711-718. PubMed ID: 31960285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
    Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
    Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
    Stamatoullas A; Ghesquières H; Feugier P; André M; Le Bras F; Gac AC; Borel C; Gastinne T; Quittet P; Morschhauser F; Ribrag V; Guidez S; Nicolas-Virelizier E; Berriolo-Riedinger A; Vander Borght T; Edeline V; Brice P
    Leuk Lymphoma; 2022 Dec; 63(13):3063-3071. PubMed ID: 35975738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.
    Kelly KM; Hutchinson RJ; Sposto R; Weiner MA; Lones MA; Perkins SL; Massey V;
    Ann Oncol; 2002; 13 Suppl 1():107-11. PubMed ID: 12078889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials.
    Zinzani PL; Viviani S; Anastasia A; Vitolo U; Luminari S; Zaja F; Corradini P; Spina M; Brusamolino E; Gianni AM; Santoro A; Botto B; Derenzini E; Pellegrini C; Argnani L
    Haematologica; 2013 Aug; 98(8):1232-6. PubMed ID: 23645687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
    Nikolaenko L; Nademanee A
    Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
    Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
    J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
    Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
    Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.